Table 4 Survival analysis according to histological lymphoma subtypes
Number | OS, % (95% CI) | EFS, % (95% CI) | TRM, % (95% CI) | CI relapse/progression, % (95% CI) | |||||
|---|---|---|---|---|---|---|---|---|---|
1 year | 2 years | 1 year | 2 years | 1 year | 2 years | 1 year | 2 years | ||
T-NOS | 110 | 72% (0.61–0.79) | 68% (0.58–0.76) | 66% (0.58–0.76) | 61% (0.52–0.71) | 16% (0.1–0.25) | 20% (0.13–0.29) | 19% (0.12–0.27) | 21% (0.13–0.29) |
AITL | 83 | 73% (0.62–0.81) | 67% (0.56–0.77) | 71% (0.61–0.82) | 64% (0.54–0.76) | 23% (0.15–0.35) | 28% (0.28–0.39) | 10% (0.03–0.17) | 12% (0.04–0.19) |
ALCL ALK+ | 21 | 81% (0.57–0.92) | 81% (0.57–0.92) | 71% (0.54–0.94) | 71% (0.54–0.94) | 5% (0.01–0.32) | 5% (0.01–0.32) | 24% (0.05–0.43) | 24% (0.05–0.43) |
ALCL ALK− | 20 | 55% (0.28–0.72) | 50% (0.28–0.68) | 52% (0.35–0.79) | 52% (0.35–0.79) | 34% (0.18–0.58) | 34% (0.18–0.58) | 14% (0–0.3) | 14% (0–0.3) |
NK/T | 16 | 50% (0.25–0.71) | 50% (0.25–0.71) | 44% (0.25–0.76) | 44% (0.25–0.76) | 29% (0.12–0.61) | 29% (0.12–0.61) | – | – |
ATLL | 16 | 56% (0.29–0.76) | 56% (0.29–0.76) | 38% (0.2–0.71) | 38% (0.2–0.71) | 25% (0.09–0.59) | 25% (0.09–0.59) | 44% (0.18–0.69) | 44% (0.18–0.69) |
HSTL | 12 | 58% (0.27–0.8) | 58% (0.27–0.8) | 64% (0.41–0.99) | 64% (0.41–0.99) | 42% (0.2–0.73) | 42% (0.2–0.73) | – | – |
EATL | 3 | 67% (0.05–0.95) | 67% (0.05–0.95) | 67% (0.3–1) | 67% ( 0.3–1) | 0 | 0 | – | – |